ASND Ascendis Pharma A/S IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1612042 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY98.0%
TTM net income YoY39.7%
TTM EPS YoY42.4%
Revenue 3-yr CAGR141.4%
Net income 3-yr CAGR—
Margins
Gross margin86.8%
Operating margin-18.9%
Net margin-31.7%
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-18.4%
ROIC (approx.)-111.1%
Asset turnover0.58x
Leverage & solvency
Liabilities / assets112.5%
Debt / equity—
Current ratio1.04x
Interest coverage-1.69x
Cash quality & payout
Operating cash flow / net income-0.24x
Accruals ratio-22.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | 720.13M | 363.64M |
| Cost of revenue | 94.92M | 44.26M |
| Gross profit | 625.22M | 319.38M |
| R&D expense | 303.62M | 307.00M |
| SG&A expense | 457.87M | 291.14M |
| Operating income | -136.27M | -278.76M |
| Interest expense | 80.65M | 65.50M |
| Pretax income | -212.65M | -373.24M |
| Income tax | 15.38M | 4.84M |
| Net income | -228.03M | -378.08M |
| EPS (basic) | -3.76 | -6.53 |
| EPS (diluted) | -3.76 | -6.53 |
| Balance sheet | ||
| Cash & equivalents | 616.04M | 559.54M |
| Receivables | 141.33M | 166.28M |
| Inventory | 301.53M | 295.61M |
| Current assets | 1.11B | 1.06B |
| PP&E, netmay include right-of-use assets (IFRS) | 146.48M | 98.71M |
| Total assets | 1.30B | 1.18B |
| Current liabilities | 1.07B | 907.86M |
| Short-term debt | 429.39M | 458.21M |
| Long-term debt | 385.25M | 365.08M |
| Total debt | 814.64M | 823.29M |
| Total liabilities | 1.47B | 1.29B |
| Shareholders' equity | -162.82M | -105.71M |
| Net debt | 198.60M | 263.74M |
| Cash flow statement | ||
| Operating cash flow | 53.90M | -306.20M |
| Investing cash flow | -8.48M | 6.88M |
| Financing cash flow | 36.33M | 443.93M |
| Stock-based compensation | 116.17M | 95.51M |
| Share buybacks | 17.40M | 0 |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.